Comparing the current results to its competitors, Harvard Apparatus Regenerative Technology Inc reported Revenue increase in the 1 quarter 2026 by 402.22 % year on year. The sales growth was above Harvard Apparatus Regenerative Technology Inc 's competitors' average revenue growth of 22.95 %, achieved in the same quarter.
Harvard Apparatus Regenerative Technology Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.
Harvard Apparatus Regenerative Technology Inc 's Comment on Competition and Industry Peers
The company is not currently aware of any direct competitors to its cell-seeded biocompatible synthetic-scaffold system. However, it may face future competition from various pharmaceutical, biotechnology, and medical device companies, many of which have greater resources. Additionally, academic and clinical centers developing regenerative technologies could become competitors. Competition factors include efficacy, safety, cost, intellectual property, marketing exclusivity under the Orphan Drug Act, supply availability, manufacturing, marketing and sales capabilities, and reimbursement coverage. The consumer health products market, particularly dietary supplements, has expanded due to increased health awareness, an aging population, and emphasis on preventive healthcare.
Due to outstanding performance in Overall company, revenue grew by 402.22 % Harvard Apparatus Regenerative Technology Inc improved its market share, to approximately 0.08 %.
Publicly Traded Peers of Harvard Apparatus Regenerative Technology Inc
Vycor Medical Inc Share Performance
-44.63%
This Year
Vycor Medical Inc
Profile
Vycor Medical Inc has a business model focused on developing and commercializing innovative medical devices and technologies in the healthcare industry.
Vericel Corporation's business model revolves around the development and commercialization of innovative cellular therapies for the treatment of severe diseases and conditions.
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics to treat various eye diseases. Their business model involves identifying promising drug candidates, conducting rigorous research and clinical trials, and seeking regulatory approvals for their products. They then partner with larger pharmaceutical companies or directly market and sell their approved therapies to healthcare providers and patients to generate revenue.
Organogenesis Holdings Inc is a regenerative medicine company that specializes in the development and commercialization of advanced wound care and surgical biologic products. Their business model revolves around leveraging their expertise in tissue engineering and biotherapeutics to create innovative products aimed at treating various chronic and acute conditions. Through strategic partnerships, they distribute their products globally to healthcare professionals and patients in need, focusing on improving patient outcomes and quality of life.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Sources:
Harvard Apparatus Regenerative Technology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Harvard Apparatus Regenerative Technology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
